Genmab AS ADR GMAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug
Trading Information
- Previous Close Price
- $53.87
- Day Range
- $51.56–52.99
- 52-Week Range
- $23.62–59.95
- Bid/Ask
- $52.23 / $52.40
- Shares Outstanding
- 616.59M
- Market Cap
- $32.28B
- Volume/Avg
- 4M / 4M
Key Statistics
- Price/Earnings (Normalized)
- 34.08
- Price/Sales
- 7.82
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 3,119
- Website
- https://www.genmab.com
Competitors
Valuation
Metric | GMAB | INCY | 4502 |
|---|---|---|---|
Price/Earnings (Normalized) | 34.08 | 49.18 | 44.04 |
Price/Book Value | 5.23 | 4.42 | 1.47 |
Price/Sales | 7.82 | 4.23 | 2.30 |
Price/Cash Flow | 34.44 | 22.78 | 15.39 |
Price/Earnings
GMAB
INCY
4502
Financial Strength
Metric | GMAB | INCY | 4502 |
|---|---|---|---|
Quick Ratio | 2.43 | 3.54 | 0.52 |
Current Ratio | 2.45 | 3.84 | 1.15 |
Interest Coverage | 2.74 | 283.92 | 1.70 |
Quick Ratio
GMAB
INCY
4502
Profitability
Metric | GMAB | INCY | 4502 |
|---|---|---|---|
Return on Assets (Normalized) | 10.39% | 9.15% | 5.67% |
Return on Equity (Normalized) | 20.28% | 11.94% | 11.63% |
Return on Invested Capital (Normalized) | 14.10% | 10.07% | 7.93% |
Return on Assets
GMAB
INCY
4502
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|FXh#<fn | LOCK|^^^^H | $139B | |||
| Moderna Inc MRNA | LOCK|FLmg$JD | LOCK|>^ | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|l%#BBx | LOCK|rR?j | $99B | |||
| argenx SE ADR ARGX | LOCK|>>Xrv&L | LOCK|<V | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|wz%h%^ | LOCK|T^ | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|fg^KPV# | LOCK|Kx>^& | $31B | |||
| Incyte Corp INCY | LOCK|BgdQ<X | LOCK|H#v | $25B | |||
| BioNTech SE ADR BNTX | LOCK|<#?t>F | LOCK|Ykl | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|hf^@Q#& | LOCK|K@v<% | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|MdMJ>hH | LOCK|Mh | $16B |
United States